Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9UB0P)

Drug Name
Oxaprozin Drug Info
Synonyms
Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
4614
ChEBI ID
CHEMBL1071
CAS Number
CAS 21256-18-8
TTD Drug ID
D0M9DC
INTEDE Drug ID
DR1212
ACDINA Drug ID
D00498

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.14 0.00e+0 101/150 (67.33%) LSM5;HSPA8;PUF60;...
DNA replication 2.10 0.00e+0 34/36 (94.44%) PCNA;FEN1;MCM2;...
Non-homologous end-joining 1.84 1.76e-2 11/13 (84.62%) FEN1;PRKDC;POLM;...
IL-17 signaling pathway -1.78 3.84e-2 84/94 (89.36%) MUC5AC;FOSL1;IKBKB;...
Mitophagy -1.80 3.84e-2 56/68 (82.35%) RRAS2;NRAS;TP53;...
Lysosome -1.84 2.56e-2 115/128 (89.84%) CLN5;AP4M1;CTSA;...
Rheumatoid arthritis -2.02 0.00e+0 78/93 (83.87%) ATP6V0C;ATP6V1D;HLA-DMB;...
Viral protein interaction with cytokine and cytokine re... -2.11 0.00e+0 84/100 (84%) CCL13;TNFRSF10C;CXCL9;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 2.5uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 2.5uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H